Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin

Clinical Cancer Research

Volumn 5, Issue 5, 1999, Pages 1189-1196

  Zeghari Squalli, Nadia ^a   Raymond, Eric ^b,c   Cvitkovic, Esteban ^a   Goldwasser, François ^a  

^a HÔPITAL PAUL BROUSSE   (France)

^b HÔPITAL SAINT ANTOINE   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; DNA TOPOISOMERASE INHIBITOR; IRINOTECAN; OXALIPLATIN; PLATINUM DERIVATIVE;

ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; COLON CANCER; CONTROLLED STUDY; DNA SYNTHESIS INHIBITION; DRUG MECHANISM; ENZYME INHIBITION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CAMPTOTHECIN; CELL CYCLE; COLONIC NEOPLASMS; CROSS-LINKING REAGENTS; DNA ADDUCTS; DNA DAMAGE; DNA TOPOISOMERASES, TYPE I; DNA, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; NUCLEIC ACID SYNTHESIS INHIBITORS; ORGANOPLATINUM COMPOUNDS; RNA, NEOPLASM; TUMOR CELLS, CULTURED;

EID: 0032905667     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Shimada, Y., Yoshino, M., Wakui, A., Nakao, I., Futatsuki, K., Sakata, Y., Kambe, M., Taguchi, T., Ogawa, N., and the CPT-11 Gastrointestinal Cancer Study Group. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J. Clin. Oncol., 11: 909-913, 1993.
2. Armand, J-P., Ducreux, M., Mahjoubi M., Abigerges, D., Bugat, R., Chabot, G., Hérait, P., De Forni, M., and Rougier, P. CPT-11 (irinotecan) in the treatment of colorectal cancer. Eur. J. Cancer, 31A: 1283-1287, 1995.
3. Bertheault-Cvitkovic, F., Jami, A., Ithzaki, M., Brummer, P. D., Brienza, S., Adam, R., Kunslinger, F., Bismuth, H., Misset, J-L., and Levi, F. Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer. J. Clin. Oncol., 14: 2950-2958, 1996.
4. de Gramont, A., Vignoud, J., Tournigand, C., Louvet, C., Andre, T., Varette, C., Raymond, E., Moreau, S., Le Bail, N., and Krulik, M. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur. J. Cancer, 33: 214-219, 1997.
5. Levi, F., Zidani, R., and Misset, J-L. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet, 350: 681-684, 1997.
6. Slichenmyer, W. J., Rowinsky, E. K., Donehower, R. C., and Kaufmann, S. H. The current status of camptothecin analogs as anticancer agents. J. Natl. Cancer Inst. (Bethesda), 85: 271-287, 1993.
7. Pommier, Y., Leteurtre, F., Fesen, M., Fujimori, A., Bertrand, R., Solary, E., Kohlhagen, G., and Kohn, K. W. Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Invest., 12: 530-542, 1994.
8. Gupta, M., Fujimori, A., and Pommier, Y. Eukaryotic DNA topoisomerase I. Biochim. Biophys. Acta, 1262: 1-14, 1995.
9. Hsiang, Y. H., Hertzberg, R., Hecht, S., and Liu, L. F. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J. Biol. Chem., 260: 14873-14878, 1985.
10. Tanizawa, A., Fujimori, A., Fujimori, Y., and Pommier, Y. Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J. Natl. Cancer Inst. (Bethesda), 86: 836-842, 1994.
11. Hsiang, Y-H., Lihou, M. G., and Liu, L. F. Arrest of DNA replication by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res., 49: 5077-5082, 1989.
12. Kawato, Y., Furuta, T., Aonuma, M., Yasuoka, M., Yokokura, T., and Matsumoto, K. Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice. Cancer Chemother. Pharmacol., 28: 192-198, 1991.
13. Giovanella, B. C., Stehlin, J. S., Wall, M. E., Wani, M. C., Nicholas, A. W., Liu, L. F., Silber, R., and Potmesil, M. DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science (Washington DC), 246: 1046-1048, 1994.
14. Chaney, S. G. The chemistry and biology of platinum complexes with the 1,2-diaminocyclohexane carrier ligand. Int. J. Oncol., 6: 1291-1305, 1995.
15. Raymond, E., Faivre, S., and Chaney, S. G. Oxaliplatin. Mechanism of action and antineoplastic activity. Semin. Oncol., 25: 4-12, 1998.
16. Fink, D., Nebel, S., Aebi, S., Zheng, H., Cenni, B., Nehme, A., Christen, R. D., and Howell, S. B. The role of DNA mismatch repair in platinum drug resistance. Cancer Res., 56: 4881-4886, 1996.
17. Rixe, O., Ortuzar, W., Alvarez, M., Parker, R., Reed, E., Paull, K., and Fojo, T. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem. Pharmacol., 52: 1855-1865, 1996.
18. Dunn, T. A., Schmoll, H. J., Grunwald, V., Bokemeyer, C., and Casper, J. Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell cancer cell lines. Invest. New Drugs, 15: 109-114, 1997.
19. Levi, F., Perpoint, B., Garufi, C., Focan, C., Chollet, P., Depres-Brummer, P., Zidani, R., Brienza, S., Ithzaki, M., Iacobelli, S., Kunslinger, F., Gastiaburu, and Misset, J-L. Oxaliplatin activity against metastatic colorectal cancer. A Phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate. Eur. J. Cancer, 29A: 1280-1284, 1993.
20. Wasserman, E., Cuvier, C., Lokiec, F., Goldwasser, F., Kalla, S., Méry-Mignard, D., Bensmaine, A., Dupont-André, G., Mahjoubi, M., Marty, M., Misset, J-L., and Cvitkovic, E. Combination of oxaliplatin (L-OHP) plus irinotecan (CPT-11) in patients with gastrointestinal tumors: results of two independent Phase I pharmacokinetic studies. J. Clin. Oncol., in press, 1999.
21. Chou, T. C., and Talalay, P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul., 22: 27-55, 1984.
22. Chou, T. C., Motzer, R. J., Tong, V., and Bosl, G. J. Computerized quantitation of synergism and antagonism of Taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J. Natl. Cancer Inst. (Bethesda), 86: 1517-1524, 1994.
23. Goldwasser, F., Valenti, M., Torres, R., and Pommier, Y. Potentiation of cisplatin cytotoxicity by 9-aminocamptothecin. Clin. Cancer Res., 2: 687-693, 1996.
24. Goldwasser, F., Shimizu, T., and Pommier, Y. Failure in DNA elongation predicts sensitivity to camptothecin in the colon cell lines of the NCI Anticancer Drug Screen. Ann. N. Y. Acad. Sci., 803: 308-310, 1996.
25. Covey, J. M., D'Incalci, M., Tilchen, E. J., Zaharko, D. S., and Kohn, K. W. Differences in DNA damage produced by incorporation of 5-aza-2′-deoxycytidine or 5,6-dihydro-5-azacytidine into DNA of mammalian cells. Cancer Res., 46: 5511-5517, 1986.
26. 2-phase arrest and the cytotoxicity of camptothecin in human colon carcinoma cells. Cancer Res., 56: 4430-4437, 1996.
27. Goldwasser, F., Bae, I., Fornace, A. J., Jr., and Pommier, Y. Differential GADD45, p21CIP1/WAF1, MCL-1 and topoisomerase II gene induction and secondary DNA fragmentation after camptothecin-induced DNA damage in two mutant p53 colon cancer cell lines. Oncol. Res., 8: 317-323, 1996.
28. Schabel, F. M., Trader, M. W., Laster, W. R., Corbett, T. H., and Griswold, D. P. cis-Dichlorodiammineplatinum(II): combination chemotherapy and croo-resistance studies with tumors of mice. Cancer Treat. Rep., 63: 1459-1473, 1979.
29. Goldwasser, F., Bae, I., Valenti, M., Torres, K., and Pommier, Y. Topoisomerase I-related parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute Anticancer Screen. Cancer Res., 55: 2116-2121, 1995.
30. Pendyala, L., Kidani, Y., Perez, R., Wilkes, J., Bernacki, R. J., and Creaven, P. J. Cytotoxicity, cellular accumulation and DNA binding of oxaliplatin isomers. Cancer Lett., 97: 177-184, 1995.
31. Raymond, E., Buquet-Fagot, C., Djelloul, S., Mester, J., Cvitkovic, E., Allain, P., Louvet, C., and Gespach, C. Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers. Anti-Cancer Drugs, 8: 876-885, 1997.
32. Minagawa, Y., Kigawa, J., Ishihara, H., Itamochi, H., and Terakawa, N. Synergistic enhancement of cisplatin cytotoxicity by SN-38, an active metabolite of CPT-11, for cisplatin-resistant HeLa cells. Jpn. J. Cancer Res., 85: 966-971, 1994.
33. el-akawi, Z., Abu-hadid, M., Perez, R., Glavy, J., Zdanowicz, J., Creaven, P. J., and Pendyala, L. Altered glutathione metabolism in oxaliplatin resistant ovarian carcinoma cells. Cancer Lett., 105: 5-14, 1996.
34. Cheng, M-F., Chatterjee, S., and Berger, N. A. Schedule-dependent cytotoxicity of topotecan alone and in combination chemotherapy regimens. Oncol. Res., 6: 269-279, 1994.
35. Fram, R. J., Rochibaud, N., Bishov, S. D., and Wilson, J. M. Interactions of cis-diamminedichloroplatinum(II) with 1-b-D-arabinofuranosylcytosine in Lovo colon carcinoma cells. Cancer Res., 47: 3360-3365, 1987.
36. Esaki, T., Nakano, S., Tatsumoto, T., Kuroki-Migita, M., Mitsugi, K., Nakamura, M., and Niho, Y. Inhibition by 5-fluorouracil of cis-diamminedichloroplatinum(II)-induced DNA interstrand cross-link removal in a HST-1 human squamous carcinoma cell line. Cancer Res., 52: 6501-6506, 1992.
37. Bergman, A. M., Ruiz van Haperen, V. W. T., Veerman, G., Kuiper, C. M., and Peters, G. J. Synergistic interaction between cisplatin and gemcitabine in vitro. Clin. Cancer Res., 2: 521-530, 1996.
38. Pourquier, P., Ueng, L-M., Kohlhagen, G., Mazumder, A., Gupta, M., Kohn, K. W., and Pommier, Y. Effects of uracil incorporation, DNA mismatches, and abasic sites on cleavage and religation activities of mammalian topoisomerase I. J. Biol. Chem., 272: 7792-7796, 1997.
39. Masuda, N., Fukuoka, M., Takada, M., Kusunoki, Y., Negoro, S., Matsui, K., Kudoh, S., Takifuji, N., Nagakawa, K., and Kishimoto, S. CPT-11 in combination with cisplatin for advanced non-small cell lung cancer. J. Clin. Oncol., 10: 1775-1780, 1992.
40. Masuda, N., Fukuoka, M., Kudoh, S., Kusunoki, Y., Matsui, N., Takifuji, N., Nagakawa, K., Tamanoi, M., Nitta, T., Hirashima, T., Negoro, S., and Takada, M. Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer. Br. J. Cancer, 68: 777-782, 1993.
41. Masuda, N., Fukuoka, M., Kudoh, S., Kusunoki Y., Matsui, K., Nagakawa, K., Hirashima, T., Tamanoi, M., Nitta, T., Yana, T., Negoro, S., Takifuji, N., and Takada, M. Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small cell lung cancer. J. Clin. Oncol., 12: 90-96, 1994.